Evaluating pancreatic cancer changes during treatment
Pancreatic Cancer Evolution Upon Treatment
NA · IRCCS San Raffaele · NCT05195281
This study is testing how pancreatic cancer changes during treatment in patients who have early-stage disease by comparing samples taken before and after chemotherapy.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | IRCCS San Raffaele (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Milan) |
| Trial ID | NCT05195281 on ClinicalTrials.gov |
What this trial studies
This project evaluates the different subtypes of pancreatic cancer through EUS-guided fine needle biopsy (FNB) sampling. It focuses on patients with non-metastatic pancreatic cancer who have undergone initial diagnostic procedures. The study aims to analyze how pancreatic cancer evolves over time by comparing initial and subsequent biopsy samples for histological diagnosis and tumor macromolecule extraction. This systematic approach could provide insights into the effectiveness of neoadjuvant chemotherapy.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with locally advanced pancreatic cancer who have undergone initial EUS-guided tissue acquisition.
Not a fit: Patients with malignancies other than pancreatic ductal adenocarcinoma or those experiencing disease progression will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding of pancreatic cancer evolution and more effective treatment strategies.
How similar studies have performed: While similar studies have explored pancreatic cancer treatment responses, this specific approach utilizing EUS-guided FNB for real-time evaluation is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Willing to sign informed consent * Patient with CT scan or MRI or EUS defining the lesion as locally advanced * Patient who already underwent EUS-TA for solid lesion of the pancreas positive for pancreatic ductal adenocarcinoma (PDAC) * Patient undergoing neoadjuvant chemotherapy * Patient primarily followed at San Raffaele Hospital Exclusion Criteria: * Patients not willing to sign informed consent * Pregnancy and breastfeeding * Cytology positive for malignancies other than PDAC * Patient undergoing progression at re-staging CT scan
Where this trial is running
Milan
- IRCCS San Raffaele Hospital — Milan, Italy (RECRUITING)
Study contacts
- Study coordinator: Livia Archibugi, MD
- Email: archibugi.livia@hsr.it
- Phone: +39-02-26432471
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Pancreatic Cancer